Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
20 hedge funds and large institutions have $21.8M invested in Bellerophon Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
350% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
54% more funds holding
Funds holding: 13 → 20 (+7)
2% less capital invested
Capital invested by funds: $22.2M → $21.8M (-$345K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.35M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$291K |
| 3 |
Renaissance Technologies
New York
|
+$194K |
| 4 |
SIM
Spark Investment Management
New York
|
+$94.3K |
| 5 |
BlackRock
New York
|
+$65.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$125K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$47.6K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$27K |
| 4 |
LPL Financial
San Diego,
California
|
-$4.08K |
BLPH Hedge Fund Activity: Q2 2017 in Review
20 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2017, worth a combined $21.8M — down 1.6% from $22.2M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new BLPH positions and 2 closed out — a net gain of 7 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $1.35M. The largest seller was Goldman Sachs, exiting entirely with an estimated $125K sold.
- 20 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2017, up from 13 in Q1 2017.
- Funds reported $21.8M of Bellerophon Therapeutics, Inc. stock for Q2 2017, down 1.6% quarter-over-quarter.
- 9 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2017 and 2 closed out, a net change of +7 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2017 was Susquehanna International Group, an estimated $1.35M added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2017 was Goldman Sachs, an estimated $125K sold.
Based on aggregated 13F filings for Q2 2017.